Placebo News and Research

RSS

BioMarin commences Phase 3b study of Kuvan's neuropsychiatric effects in phenylketonuria patients

BioMarin Pharmaceutical Inc. announced today that the first subject has initiated treatment in a Phase 3b study (PKU-016) to evaluate the effects of Kuvan (sapropterin dihydrochloride) on neuropsychiatric symptoms in subjects with phenylketonuria (PKU). BioMarin expects to report results in the first half of 2012.

18 Aug 2010

Acupuncture not superior to sham acupuncture in knee osteoarthritis

17 Aug 2010

Study finds sham acupuncture superior to traditional Chinese acupuncture in osteoarthritis treatment

Researchers from MD Anderson Cancer Center determined patients with osteoarthritis (OA) of the knee who are treated with traditional Chinese acupuncture (TCA) do not experience any more benefit than those receiving sham acupuncture (placebo). The team did find that the communication style of the acupuncturist could have a significant effect on pain reduction and satisfaction in patients. Full findings are now online and will publish in the September print issue of Arthritis Care & Research, a journal of the American College of Rheumatology.

17 Aug 2010

Palatin reports positive results from bremelanotide Phase 1 trial for sexual dysfunction

Palatin Technologies, Inc. today announced positive results of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD). The results demonstrate that with subcutaneous administration consistent therapeutic blood plasma levels can be obtained without sustained clinically significant blood pressure effects and support the continued development of bremelanotide.

17 Aug 2010

Ancient discovery holds key to joint tissue regeneration

Osteoarthritis is a crippling disease worldwide, with an estimated eight million sufferers in the UK alone. It has been described as like "wearing a suit of rusty armour," with unrelenting, razor-like pain.

17 Aug 2010

Intercell reports significant increase in second quarter revenue

Today, Intercell AG announced its financial results for Q2 and H1 2010.IXIARO/JESPECT sales increased significantly from EUR 2.4m in Q2 2009 to EUR 5.2m in Q2 2010 Continued focus on growing marketing and sales of product in traveler and military markets

17 Aug 2010

Antidepressant alleviates depression in peri- and postmenopausal women: Study

An antidepressant can alleviate symptoms of major depression in women experiencing or about to experience menopause, according to a study released today led by a Virginia Commonwealth University researcher.

17 Aug 2010

Nile Therapeutics second quarter 2010 net loss decreases to $1.5 million

Nile Therapeutics, Inc.,a company focused on the development of novel therapeutics for heart failure patients, today announced its second quarter financial results for 2010.

16 Aug 2010

NIDA grants Selecta Biosciences $3M to develop nicotine vaccine for smoking cessation and relapse prevention

Selecta Biosciences, Inc., a biopharmaceutical company developing synthetic nanoparticle vaccines and immunotherapies, today announced that it has been awarded a grant for $3 million from the National Institute on Drug Abuse (NIDA), an institute within the U.S. National Institutes of Health. The grant is aimed at advancing the development of an enhanced therapeutic nicotine vaccine for the treatment of smoking cessation and relapse prevention.

16 Aug 2010

Adeona reports $979,782 net income for second-quarter 2010 vs. $879,550 net loss for same period in 2009

Adeona Pharmaceuticals, Inc. announced its second quarter 2010 financial results and recent achievements.

16 Aug 2010

Use of estrogen alone does not increase lung cancer mortality in postmenopausal women: Study

Use of estrogen alone did not increase lung cancer mortality in postmenopausal women, according to a study published online August 13 in The Journal of the National Cancer Institute. In the Women's Health Initiative (WHI) trial, which consisted of several clinical trials on postmenopausal women, one study showed women with previous hysterectomy taking combined estrogen plus progestin therapy had a statistically significant increase in lung cancer mortality, but not incidence. Other studies with combined hormone therapy have had conflicting results. But the influence of estrogen alone was unclear.

16 Aug 2010

Soligenix’s net loss for second-quarter 2010 decreases to $1,577,000

Soligenix, Inc., a late-stage biopharmaceutical company, announced today its financial results for the second quarter of 2010.

13 Aug 2010

CRF announces additional featured trials to be presented at Transcatheter Cardiovascular Therapeutics 2010

The Cardiovascular Research Foundation has announced that in addition to the previously announced late breaking clinical trials and first reports, a series of additional featured trials will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 scientific symposium. These trials will focus on a wide range of significant topics in interventional cardiovascular medicine. TCT 2010 will take place September 21 - 25 in Washington, DC.

13 Aug 2010

Novavax announces positive results from pre-clinical toxicology study of RSV vaccine candidate

Novavax, Inc. reported today that results from a pre-clinical toxicology study of its vaccine candidate to prevent respiratory syncytial virus, showed the vaccine to be safe and well-tolerated at all doses tested. Novavax's vaccine uses highly purified recombinant particles of RSV-F fusion protein normally found in the virus. There is currently no approved vaccine to prevent RSV infection.

13 Aug 2010

Early administration of TXA reduces death from bleeding without increase in complications: Study

If recently injured patients with serious bleeding were to receive a cheap, widely available and easily administered drug to help their blood to clot, tens of thousands of lives could be saved every year, according to a paper published on-line today by The Lancet.

12 Aug 2010

FDA advisory committee votes in favor of investigational anti-epileptic drug ezogabine

GlaxoSmithKline and Valeant Pharmaceuticals International announced today that a U.S. Food and Drug Administration advisory committee voted unanimously that clinical studies had provided substantial evidence of the effectiveness of ezogabine as adjunctive treatment for adults with partial-onset seizures.

12 Aug 2010

Syndax raises $6 million to support ENCORE 301 study in breast cancer

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that it has issued $6M in convertible notes and warrants to its Series A investors bringing the total investment to date to $55M. All current investors, including Domain Associates, MPM Capital, Avalon Ventures, Forward Ventures, Pappas Ventures and MC Life Sciences participated in the securities offering.

12 Aug 2010

Protox reports $1.1M net income for second-quarter 2010 vs. $1.8M net loss for second-quarter 2009

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today released financial results for the second quarter 2010, ended June 30, 2010.

11 Aug 2010

Depomed announces SPA agreement with FDA for Serada Phase 3 trial for menopausal hot flashes

Depomed, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration regarding a Special Protocol Assessment on the design and analysis of Breeze 3, a Phase 3 trial evaluating Serada® (extended release gabapentin tablets) for menopausal hot flashes.

11 Aug 2010

Repros receives US patent for Androxal

Repros Therapeutics Inc. today announced the US Patent and Trademark office has issued U.S. Patent No. 7,759,360 for Androxal, the Company's lead program for the treatment of low testosterone in men. This patent specifically claims methods and materials for the treatment of testosterone deficiency in men with secondary hypogonadism. Repros has over 35 issued or pending US and European patents involving Androxal.

11 Aug 2010

Placebo News and Research

BioMarin commences Phase 3b study of Kuvan's neuropsychiatric effects in phenylketonuria patients

Acupuncture not superior to sham acupuncture in knee osteoarthritis

Study finds sham acupuncture superior to traditional Chinese acupuncture in osteoarthritis treatment

Palatin reports positive results from bremelanotide Phase 1 trial for sexual dysfunction

Ancient discovery holds key to joint tissue regeneration

Intercell reports significant increase in second quarter revenue

Antidepressant alleviates depression in peri- and postmenopausal women: Study

Nile Therapeutics second quarter 2010 net loss decreases to $1.5 million

NIDA grants Selecta Biosciences $3M to develop nicotine vaccine for smoking cessation and relapse prevention

Adeona reports $979,782 net income for second-quarter 2010 vs. $879,550 net loss for same period in 2009

Use of estrogen alone does not increase lung cancer mortality in postmenopausal women: Study

Soligenix’s net loss for second-quarter 2010 decreases to $1,577,000

CRF announces additional featured trials to be presented at Transcatheter Cardiovascular Therapeutics 2010

Novavax announces positive results from pre-clinical toxicology study of RSV vaccine candidate

Early administration of TXA reduces death from bleeding without increase in complications: Study

FDA advisory committee votes in favor of investigational anti-epileptic drug ezogabine

Syndax raises $6 million to support ENCORE 301 study in breast cancer

Protox reports $1.1M net income for second-quarter 2010 vs. $1.8M net loss for second-quarter 2009

Depomed announces SPA agreement with FDA for Serada Phase 3 trial for menopausal hot flashes

Repros receives US patent for Androxal

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News